Loading
Sonendo, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 23 May 2024.
Sonendo, Inc.: what insiders have been doing
Sonendo, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). The past year has been quiet: not a single insider filing for Sonendo, Inc. The previous disclosure was published on 19 September 2024.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
160
Thresholds
n/a
Buy Volume
€1M
30 ops. · all time
Sell Volume
€1M
71 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
US$0.97
Analyst consensus
Income statement
RevenueUS$31.7M
Gross profitUS$11.8M37% margin
EBITDA-US$26.6M-84% margin
Net income-US$28M-88.4% margin
Valuation
P/Book0.1x
Beta1.82
Balance sheet & cash
Market capUS$4.6M
Total debtUS$17.8M
Free Cash Flow-US$24.8M
Debt / Equity344%
Profitability & ownership
ROE-199.6%
ROA-33.3%
% insiders1.1%
% institutions0.0%
Last declaration on 19 September 2024
Declarations160 total
500,000 shares0Common StockSEC:0000950170-24-108217:0
200,000 shares0Common StockSEC:0000950170-24-108197:0
200,000 shares0Common StockSEC:0000950170-24-108201:0
200,000 shares0Common StockSEC:0000950170-24-108193:0
600,000 shares0Common StockSEC:0000950170-24-108215:0
200,000 shares0Common StockSEC:0000950170-24-108204:0
1,600,000 shares0Common StockSEC:0000950170-24-108209:0
43,240 shares@ US$0.08660.8% of flowCommon StockSEC:0000950170-24-076612:0
8,510 shares@ US$0.08611.0% of flowCommon StockSEC:0000950170-24-076614:0
720,000 shares0Common StockSEC:0000950170-24-069750:0
10,901 shares@ US$0.09097.9% of flowCommon StockSEC:0001562180-24-004459:0
116,500 shares@ US$0.099192.1% of flowCommon StockSEC:0001562180-24-004346:0
Canonical exit: 20 Aug 2024 (T+90)
520,000 shares@ US$0.095253.5% of flowCommon StockSEC:0001562180-24-004140:0
Canonical exit: 14 Aug 2024 (T+90)
500,000 shares@ US$0.0949.8% of flowCommon StockSEC:0001562180-24-004037:0
Canonical exit: 12 Aug 2024 (T+90)
774 shares@ US$0.0910.1% of flowCommon StockSEC:0001562180-24-003857:0
2,381 shares@ US$0.0910.0% of flowCommon StockSEC:0001562180-24-003858:0
2,625 shares@ US$0.10430.4% of flowCommon StockSEC:0001562180-24-003026:0
11,493 shares@ US$0.10430.3% of flowCommon StockSEC:0001562180-24-003025:0
5,359 shares@ US$0.09670.7% of flowCommon StockSEC:0001562180-24-002776:0
10,670 shares@ US$0.09670.9% of flowCommon StockSEC:0001562180-24-002775:0
800,000 shares@ US$0.1016.6% of flowCommon StockSEC:0001562180-24-002778:0
Canonical exit: 13 Jun 2024 (T+90)
23,351 shares@ US$0.09670.5% of flowCommon StockSEC:0001562180-24-002777:0
2,685 shares@ US$0.1510.1% of flowCommon StockSEC:0001562180-24-001079:0
25 of 160 declarations
About Sonendo, Inc.
Sonendo, Inc. is a U.S.-based medical technology company operating in the United States and listed on the OTC market under the ticker SONX, rather than on the NYSE or NASDAQ at present. Headquartered in Laguna Hills, California, the company focuses on a highly specialized segment of dental healthcare: endodontics. Its flagship platform is the GentleWave® System, an advanced root-canal cleaning and disinfection technology designed to help preserve tooth structure while reducing the invasiveness of conventional treatment.
Sonendo’s business model is centered on the development, manufacturing, and commercialization of a proprietary procedural platform used by dental professionals. The GentleWave System combines fluid dynamics and acoustic energy to clean and disinfect the microscopic spaces inside teeth. Management positions the technology as a clinically meaningful alternative to traditional root-canal approaches because it aims to remove less tooth structure and deliver more effective cleaning in complex anatomy. In practical terms, the company’s offering is not just a one-off device sale: it also includes procedure-related consumables and accessories, which can support recurring revenue over time if adoption expands.
Read moreShow less
Founded to improve the standard of care in root-canal therapy, Sonendo built its identity around a single, focused therapeutic category. That narrow specialization is a strategic strength and a risk. On the positive side, it gives the company clear differentiation, a strong clinical narrative, and a premium technology positioning. On the other hand, it exposes Sonendo to adoption risk, reimbursement and budget sensitivity at the dental-practice level, and the challenge of convincing practitioners to change established workflows. Competitive pressure comes from conventional endodontic tools and systems, alternative disinfection methods, and lower-cost treatment solutions. Sonendo therefore competes more on clinical differentiation and workflow value than on scale.
Geographically, the company appears primarily centered on the U.S. market, with operations and corporate presence anchored in Southern California. Recent company communications indicate that management has been executing a strategic reset since early 2024, with priorities including revenue stabilization, gross margin improvement, lower operating expenses, and reduced cash burn. In 2025, Sonendo also completed a $5.0 million private placement and continued restructuring efforts, highlighting the company’s focus on liquidity and the path toward breakeven. For investors, Sonendo should be viewed as a niche dental-medtech small-cap with meaningful technology upside, but also elevated execution and financing risk. As a U.S. issuer tied to the healthcare sector, it remains a closely watched name for operational turnaround and insider-activity analysis.
